Pharmaceutically active disubstituted triazine derivatives

Details for Australian Patent Application No. 2011231975 (hide)

Owner Lead Discovery Center GmbH Bayer Intellectual Property GmbH

Inventors Eickhoff, Jan; Nussbaumer, Peter; Ruhter, Gerd; Schultz-Fademrecht, Carsten; Lucking, Ulrich; Choidas, Axel; Klebl, Bert

Agent Davies Collison Cave

Pub. Number AU-A-2011231975

PCT Pub. Number WO2011/116951

Priority 10075131.2 22.03.10 EP; 61/282,766 29.03.10 US

Filing date 20 March 2011

Wipo publication date 29 September 2011

International Classifications

C07D 251/22 Heterocyclic compounds containing 1,3,5-triazine rings

A61K 31/53 - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 35/00 Antineoplastic agents

A61P 37/00 Drugs for immunological or allergic disorders

C07D 401/04 Heterocyclic compounds containing two or more hetero rings

C07D 401/12 Heterocyclic compounds containing two or more hetero rings

C07D 403/12 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 407/04 Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group

Event Publications

30 August 2012 PCT application entered the National Phase

  PCT publication WO2011/116951 Priority application(s): WO2011/116951

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011231976-A garment, in particular a compression garment for medical use

2011231953-Method and apparatus for determining at least one evaluation parameter of at least one blood sample